Filtros de búsqueda

Lista de obras de Sara A. Hurvitz

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients

artículo científico publicado en 2012

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer

artículo científico

Clinical features of pseudocirrhosis in metastatic breast cancer

artículo científico publicado en 2019

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

artículo científico publicado en 2011

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy

artículo científico publicado en 2019

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

artículo científico publicado en 2020

Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

scientific article published on 01 September 2018

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response

artículo científico publicado en 2021

Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

scientific article published on 25 November 2019

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

scientific article published on 20 August 2020

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda